Evonik develops system solutions for the gut health of poultry and swine
- Science-based system solutions that include low-protein diets, amino acids, probiotics, services and consulting
- Tailored to the specific challenges of broiler chickens, laying hens and pigs
- Focus on the interplay between animal health, productivity and profitability
Evonik has developed science-based system solutions for the gut health of broiler chickens, laying hens and weaned to growing-finishing pigs. This integrated approach makes it possible to keep animals healthy without the use of antibiotics, and to produce meat and eggs in a sustainable and economically profitable manner.
Evonik’s new system solutions for gut health include a tailored combination of its feeding concepts, amino acids, probiotics, services and consulting, depending on the individual needs and challenges of the customer. The approach means the customer receives better economic, animal welfare and sustainability results whatever their circumstances.
"The challenges for farmers in increasing productivity while maintaining healthy animals are manifold and can only be overcome with comprehensive solutions," says Dr. Torben Madsen, head of the Sustainable Healthy Nutrition product line at Evonik. "Our new gut health system solutions provide the basis for solving those challenges".
The intestinal microbiota, i.e., the totality of microorganisms in the digestive system, is at the center of the solution. Maintaining its sensitive balance depends on various factors. Among these, feeding is an important aspect that can stabilize or unbalance the microbiota. Environmental conditions such as heat stress or piglets at weaning from breast milk also impact the microbial balance. Ultimately, antibiotics or pathogens have an immediate effect on the microbiota.
As a result, morphological and functional changes occur in the gut which negatively affect digestion and thus nutrient absorption. This leads to reduced animal growth or even increased mortality.
"It is important to understand these complex gut systems and target them individually with the right solutions," says Dr. Xu Wang, product manager for Gut Health Solutions at Evonik Animal Nutrition. "Our products and services make a significant contribution to this and we are more than happy to introduce our customers to our system solutions".
The new gut health system solutions, which are all based upon scientific studies, will be presented to the professional public for the first time at the ‘All About Feed Forum’. From May 13 visitors will have access to the platform and on May 27 there will be an online event, including two Evonik presentations:
- Key challenges in broiler gut health - Nadia Yacoubi, research manager for Poultry Nutrition, Evonik, from 1:30 to 1:50 pm CEST in the Livestock Area
- Holistic approach to enhance gut health - John Htoo, Director Technical Consultancy, Evonik, from 3:00 to 3:20 pm CEST on the Feed Stage
To join Evonik at the event see: https://get.allaboutfeed.net/virtual-all-about-feed-forum/
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.